journal article·2023-02Open access

Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors

Siyuan Tang, Ekta Kapoor, Ling Ding, Ao Yu, Weimin Tang, Yu Hang, Lynette M. Smith, Diptesh Sil, David Oupický

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a five-year survival rate of around 10 %. CXCR4 and STAT3 display crucial effects on proliferation, metastasis, angiogenesis, and formation of immunosuppressive microenvironment in pancreatic tumors. Here, we have tested the hypothesis that conjugation of α-tocopherol (TOC) to a polycation (PAMD), synthesized from CXCR4-antagonist AMD3100, will improve delivery of therapeutic siRNA to silence STAT3 in PDAC tumors. PAMD-TOC/siSTAT3 nanoparticles showed superior anti-cancer and anti-migration performance compared to the parent PAMD/siSTAT3 nanoparticles in both murine and human PDAC cell lines. The biodistribution of the nanoparticles in orthotropic mouse KPC8060 and human PANC-1 models, indicated that tumor accumulation of PAMD-TOC/siRNA nanoparticles was improved greatly as compared to PAMD/siRNA nanoparticles. This improved cellular uptake, penetration, and tumor accumulation of PAMD-TOC/siSTAT3 nanoparticles, also contributed to the suppression of tumor growth, metastasis and improved survival. Overall, this study presents a prospective treatment strategy for PDAC.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: MicroRNA in disease regulation · Cancer Cells and Metastasis · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Cancer statistics, 2021
2. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–201010.3748/wjg.v17.i7.867 ↗
3. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes10.3748/wjg.v24.i43.4846 ↗
4. Early detection of pancreatic cancer: opportunities and challenges10.1053/j.gastro.2019.01.259 ↗
5. Symptom management in pancreatic cancer10.1007/s11864-020-00801-4 ↗
8. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches10.1186/s13014-019-1345-6 ↗
9. Advanced-stage pancreatic cancer: therapy options10.1038/nrclinonc.2013.66 ↗
10. Management problems in patients with pancreatic cancer from a surgeon's perspective10.1053/j.seminoncol.2021.02.008 ↗
11. Regulation of tumor microenvironment for pancreatic cancer therapy10.1016/j.biomaterials.2021.120680 ↗
12. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential10.7150/thno.4922 ↗
13. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer10.1186/s12885-016-2143-2 ↗
14. Prognosis and clinicopathology of CXCR4 in colorectal cancer patients: a meta-analysis10.7314/APJCP.2015.16.9.4077 ↗
15. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy10.1016/j.pharmthera.2017.05.012 ↗
16. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial–mesenchymal transition in vitro through non-canonical activation of hedgehog pathway10.1016/j.canlet.2012.02.035 ↗
17. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer
18. Effect of CXCL12 and its receptors on unpredictable renal cell carcinoma10.1016/j.clgc.2019.11.004 ↗
19. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies10.1016/j.semcancer.2019.12.007 ↗
20. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer
21. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
22. Knockdown of CXCR4 inhibits CXCL12-induced angiogenesis in HUVECs through downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-catenin pathways10.1080/07357907.2017.1422512 ↗
23. CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy10.1038/sj.bjc.6605968 ↗
24. Intraperitoneal siRNA nanoparticles for augmentation of gemcitabine efficacy in the treatment of pancreatic cancer10.1021/acs.molpharmaceut.1c00653 ↗
25. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer10.1126/science.1171362 ↗
26. Targeting the IL-6/JAK/STAT3 signalling axis in cancer10.1038/nrclinonc.2018.8 ↗
27. STAT3 as an emerging molecular target in pancreatic cancer
28. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression10.1016/j.ccr.2011.03.002 ↗
29. Role of STAT3 signaling pathway in breast cancer10.1186/s12964-020-0527-z ↗
30. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies10.1016/j.semcancer.2017.06.001 ↗
31. Novel activators and small-molecule inhibitors of STAT3 in cancer10.1016/j.cytogfr.2019.10.005 ↗
32. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer10.1016/j.ccr.2011.03.009 ↗
33. STAT3 and apoptosis challenges in cancer10.1016/j.ijbiomac.2018.05.121 ↗
34. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis10.1038/sj.onc.1207383 ↗
35. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment10.1038/nri1995 ↗
36. STATs in cancer inflammation and immunity: a leading role for STAT310.1038/nrc2734 ↗
37. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric plerixafor10.1016/j.biomaterials.2014.03.047 ↗
38. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting nanoparticles10.1039/C5BM00003C ↗
39. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA/siRNA nanotherapy10.1021/acsnano.9b03978 ↗
40. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer10.1016/j.jconrel.2021.03.028 ↗
41. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer10.1021/mp100012s ↗
42. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice10.1016/j.ijpharm.2015.09.030 ↗
43. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol10.1038/mt.2008.14 ↗
44. Chimeric antisense oligonucleotide conjugated to α-tocopherol
45. Nucleic acid delivery with α-tocopherol-polyethyleneimine-polyethylene glycol nanocarrier system10.2147/IJN.S259724 ↗
46. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol10.1038/mt.2008.14 ↗
47. Polymeric plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection10.1007/s11095-014-1440-1 ↗
48. Development of α-tocopherol surface-modified targeted delivery of 5-fluorouracil-loaded poly-D,L-lactic-co-glycolic acid nanoparticles against oral squamous cell carcinoma10.4103/jcrt.JCRT_263_18 ↗
49. Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery10.1016/j.biomaterials.2010.09.027 ↗
50. Nanoemulsion-assisted siRNA delivery to modulate the nervous tumor microenvironment in the treatment of pancreatic cancer10.1021/acsami.1c21997 ↗
51. STAT3 down-regulation induces mitochondria-dependent G2/M cell cycle arrest and apoptosis in oesophageal carcinoma cells10.1111/1440-1681.12708 ↗
52. CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a/16-1-mediated ERK and BCL2/Cyclin D1 pathways10.1158/0008-5472.CAN-17-0454 ↗
53. Targeting STAT3 in cancer immunotherapy10.1186/s12943-020-01258-7 ↗
54. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer10.1073/pnas.1815515116 ↗
55. Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival10.1053/j.gastro.2016.03.010 ↗